

Small Intestine

Protocol applies to all invasive carcinomas of the small intestine, including those with focal endocrine differentiation. Excludes carcinoid tumors, lymphomas, and stromal tumors (sarcomas).

*Protocol revision date: January 2005
Based on AJCC/UICC TNM, 6th edition*

Procedures

- **Cytology** (No Accompanying Checklist)
- **Incisional Biopsy** (No Accompanying Checklist)
- **Excisional Biopsy (Polypectomy)**
- **Segmental Resection**
- **Pancreaticoduodenectomy, Partial or Complete, With or Without Partial Gastrectomy (Whipple Resection)**

Author

Carolyn Compton, MD, PhD

Department of Pathology, McGill University, Montreal, Quebec, Canada
For the Members of the Cancer Committee, College of American Pathologists

Previous contributors: Stephen G. Ruby, MD; Gregorio Chejfec, MD; John A. Payne, MD; Jerome B. Taxy, MD; Kay Washington, MD; Christopher Willett, MD; James Williams, MD

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

Summary of Changes to Checklist(s)

Protocol revision date: January 2005

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005
Applies to invasive carcinomas only
Based on AJCC/UICC TNM, 6th edition*

**SMALL INTESTINE: Polypectomy, Segmental Resection,
Pancreaticoduodenectomy, Partial or Complete, With or
Without Partial Gastrectomy (Whipple Resection)**

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC**Specimen Type**

- Polypectomy
 Segmental resection
 Whipple resection
 Other (specify): _____
 Not specified

Tumor Site

- Duodenum
 Jejunum
 Ileum
 Not specified

***Tumor Configuration**

- * Exophytic (polypoid)
 * Infiltrative
 * Ulcerating
 * Other (specify): _____

Tumor Size

- Greatest dimension: ____ cm
 *Additional dimensions: ____ x ____ cm
 Cannot be determined (see Comment)

Other Organs Received

- None
 Specify: _____

4 * Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

MICROSCOPIC**Histologic Type**

- Adenocarcinoma (not otherwise characterized)
- Mucinous adenocarcinoma (greater than 50% mucinous)
- Signet-ring cell carcinoma (greater than 50% signet-ring cells)
- Small cell carcinoma
- Squamous cell carcinoma
- Adenosquamous carcinoma
- Medullary carcinoma
- Undifferentiated carcinoma
- Mixed carcinoid-adenocarcinoma
- Other (specify): _____
- Carcinoma, type cannot be determined

Histologic Grade

- Not applicable
- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- G4: Undifferentiated
- Other (specify): _____

Pathologic Staging (pTNM)Primary Tumor (pT)

- pTX: Cannot be assessed
- pT0: No evidence of primary tumor
- pTis: Carcinoma in situ
- pT1: Tumor invades lamina propria or submucosa
- pT2: Tumor invades muscularis propria
- pT3: Tumor invades through the muscularis propria into the subserosa or the nonperitonealized perimuscular tissue with extension of 2 cm or less
- pT4: Tumor perforates the visceral peritoneum or directly invades other organs or structures

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed
- pN0: No regional lymph node metastasis
- pN1: Metastasis in regional lymph nodes
- Specify: Number examined: ____
- Number involved: ____

Distant Metastasis (pM)

- pMX: Cannot be assessed
- pM1: Distant metastasis
- *Specify site(s), if known: _____

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Margins (check all that apply)

Polypectomy Specimens Only

Mucosal Margin

- Cannot be assessed
- Uninvolved by carcinoma
- Involved by carcinoma
- Involved by adenoma

Deep Margin

- Cannot be assessed
- Uninvolved by carcinoma
- Distance of carcinoma from margin: ___ mm
- Involved by carcinoma

Segmental Resection or Pancreaticoduodenectomy (Whipple)

Proximal (Small Bowel or Stomach) Margin

- Cannot be assessed
- Uninvolved by invasive carcinoma
- Involved by invasive carcinoma
- Carcinoma in situ/adenoma absent at proximal margin
- Carcinoma in situ/adenoma present at proximal margin
- Carcinoma in situ/adenoma not applicable (gastric margin)

Distal (Bowel) Margin

- Cannot be assessed
- Uninvolved by invasive carcinoma
- Involved by invasive carcinoma
- Carcinoma in situ/adenoma absent at distal margin
- Carcinoma in situ/adenoma present at distal margin

Circumferential/Radial (Mesenteric or Retroperitoneal) Margin

- Cannot be assessed
- Uninvolved by invasive carcinoma
- Involved by invasive carcinoma

Bile Duct Margin

- Not applicable
- Cannot be assessed
- Margin uninvolved by invasive carcinoma
- Margin involved by invasive carcinoma

6 * Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Pancreatic Margin

- Not applicable
 Cannot be assessed
 Margin uninvolved by invasive carcinoma
 Margin involved by invasive carcinoma

If all margins uninvolved by invasive carcinoma:

Distance of invasive carcinoma from closest margin: ___ mm OR ___ cm

*Specify margin (if possible): _____

***Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)**

- * Absent
 * Present
 * Indeterminate

***Perineural Invasion**

- * Absent
 * Present
 * Indeterminate

***Additional Pathologic Findings (check all that apply)**

- * None identified
 * Adenoma(s)
 * Crohn disease
 * Celiac disease
 * Epithelial dysplasia
 * Other polyps (type[s]): _____
 * Other (specify): _____

***Comment(s)**

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Background Documentation

Protocol revision date: January 2005

I. Cytologic Material

A. Clinical Information

1. Patient identification
 - a. Name
 - b. Identification number
 - c. Age (birth date)
 - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
 - a. Relevant history (Note **A**)
 - b. Relevant findings (eg, endoscopic/imaging studies)
 - c. Clinical diagnosis
 - d. Procedure (eg, fine-needle aspiration [FNA], scraping, brushing)
 - e. Operative findings
 - f. Anatomic sites (eg, duodenum, jejunum, ileum: endoscopic distance)

B. Macroscopic Examination

1. Specimen
 - a. Description
 - b. Type (cell block, slides, cytospins, fluids, other)
 - c. Unfixed/fixed (specify fixative)
 - d. Number of slides received
 - e. Quantity and appearance of fluid specimen
 - f. Other (eg, tissue received for cytologic preparation)
 - g. Results of intraprocedural consultation (Note **B**)
2. Material submitted for microscopic evaluation (eg, smear, cytocentrifuge, touch or filter preparation, cell block)
3. Special studies (specify) (Note **C**)

C. Microscopic Evaluation

1. Adequacy of specimen (if unsatisfactory for evaluation, specify reason)
2. Tumor, if present
 - a. Histologic type, if possible (Note **D**)
 - b. Histologic grade, if possible (Note **E**)
 - c. Other descriptive information (eg, hemorrhage, necrosis)
3. Additional pathologic findings, if present
4. Special studies (Note **C**)
5. Comments
 - a. Correlation with intraprocedural consultation, as appropriate
 - b. Correlation with other specimens, as appropriate
 - c. Correlation with clinical information, as appropriate

II. Incisional Biopsy (Endoscopic or Other)

A. Clinical Information

1. Patient identification
 - a. Name
 - b. Identification number
 - c. Age (birth date)
 - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
 - a. Relevant history (Note **A**)
 - b. Relevant findings (eg, endoscopic/imaging studies)
 - c. Clinical diagnosis
 - d. Procedure (eg, endoscopic biopsy)
 - e. Operative findings
 - f. Anatomic sites (eg, duodenum, jejunum, ileum: endoscopic distance)

B. Macroscopic Examination

1. Specimen(s)
 - a. Tissues submitted
 - b. Unfixed/fixed (specify fixative)
 - c. Number of pieces
 - d. Dimensions
 - e. Descriptive features (eg, color, consistency, configuration)
 - f. Layers of bowel, if discernible
 - g. Results of intraoperative consultation
2. Tissues submitted for microscopic evaluation
 - a. All biopsy material
 - b. Frozen section tissue fragment(s)
3. Special studies (specify) (eg, histochemistry, immunohistochemistry [designate each antibody], morphometry, DNA analysis [specify type], electron microscopy, cytogenetic analysis) (Note **C**)

C. Microscopic Evaluation

1. Tumor
 - a. Histologic type (Note **D**)
 - b. Histologic grade (Note **E**)
 - c. Extent of invasion (Note **F**)
 - d. Venous/lymphatic vessel invasion
2. Additional pathologic findings, if present
 - a. Benign neoplasms
 - b. Dysplasia
 - c. Crohn disease
 - d. Celiac disease
 - e. Other(s)
2. Results/status of special studies (specify)
3. Comments
 - a. Correlation with intraoperative consultation, as appropriate
 - b. Correlation with other specimens, as appropriate
 - c. Correlation with clinical information, as appropriate

III. Excisional Biopsy

(Local Excision, Polypectomy)

A. Clinical Information

1. Patient identification
 - a. Name
 - b. Identification number
 - c. Age (birth date)
 - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
 - a. Relevant history (Note **A**)
 - b. Relevant findings (eg, endoscopic/imaging studies)
 - c. Clinical diagnosis
 - d. Procedure (eg, polypectomy)
 - e. Operative findings
 - f. Anatomic sites (eg, duodenum, jejunum, ileum: endoscopic distance)

B. Macroscopic Examination

1. Specimen
 - a. Tissue(s) submitted
 - b. Unfixed/fixed (specify fixative)
 - c. Number of pieces
 - d. Dimensions
 - e. Descriptive features (eg, color, consistency, configuration)
 - f. Orientation, if designated by surgeon
 - g. Results of intraoperative consultation
2. Tissue submitted for microscopic evaluation
 - a. Coronal section of polyp(s) through resection margin or stalk, if applicable
 - b. All other tissue from polypectomy specimen(s)
 - c. Frozen section tissue fragment(s)
3. Special studies (specify) (eg, histochemistry, immunohistochemistry, morphometry, DNA analysis [specify type], cytogenetic analysis) (Note **C**)

C. Microscopic Evaluation

1. Tumor
 - a. Histologic type (Note **D**)
 - b. Histologic grade (Note **E**)
 - c. Depth of invasion, as appropriate (Note **F**)
 - d. Venous/lymphatic vessel invasion
 - e. Interface with adjacent normal mucosa
 - f. Distance (millimeters) between tumor and closest margin(s)
2. Additional pathologic findings, if present
 - a. Benign neoplasms
 - b. Dysplasia
 - c. Crohn disease
 - d. Celiac disease
 - e. Other(s)
3. Other tissue(s)/organ(s)
4. Results/status of special studies (specify) (Note **C**)
5. Comments
 - a. Correlation with intraoperative consultation, as appropriate
 - b. Correlation with other specimens, as appropriate
 - c. Correlation with clinical information, as appropriate

IV. Segmental Resection

A. Clinical Information

1. Patient identification
 - a. Name
 - b. Identification number
 - c. Age (birth date)
 - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
 - a. Relevant history (Note **A**)
 - b. Relevant findings (eg, endoscopic/imaging studies)
 - c. Clinical diagnosis
 - d. Procedure (eg, distal ileal resection)
 - e. Operative findings
 - f. Anatomic sites (eg, duodenum, jejunum, ileum)

B. Macroscopic Examination

1. Specimen
 - a. Organ(s)/tissue(s) submitted
 - b. Previously opened
 - c. Unfixed/fixed (specify fixative)
 - d. Number of pieces
 - e. Dimensions (length, circumference)
 - f. Descriptive characteristics (eg, thickness of bowel wall in abnormal areas)
 - g. Orientation (if designated by surgeon)
 - h. Results of intraoperative consultation
2. Tumor
 - a. Location
 - b. Configuration (Note **G**)
 - c. Size (3 dimensions)
 - d. Descriptive features (eg, color, consistency, hemorrhage)
 - e. Relationship to mesenteric border
 - f. Ulceration
 - g. Obstruction/perforation
 - h. Proximal dilatation
 - i. Depth of invasion (layers of bowel present at lesion site, if discernible)
 - j. Status of overlying serosa
 - k. Extension to other organ(s)/structure(s)
3. Margins (Note **H**)
 - a. Proximal
 - b. Distal
 - c. Mesenteric (radial), if applicable
4. Regional lymph nodes (Note **B**)
5. Additional pathologic findings, if present
 - a. Adenomatous polyps (polyposis syndrome)
 - b. Hamartomatous polyps (polyposis syndrome)
 - c. Crohn disease
 - d. Celiac disease
 - e. Other
6. Metastasis to other organ(s) or structure(s) (specify)

7. Tissues submitted for microscopic evaluation
 - a. Tumor
 - (1) point of deepest penetration
 - (2) overlying serosa
 - (3) interface with adjacent tissue
 - (4) interface with uninvolved adjacent bowel
 - b. Margins (as appropriate) (Note **H**)
 - c. All lymph nodes
 - d. Other lesions (eg, polyps, ulcers, fistulas)
 - e. Section(s) of bowel uninvolved by tumor
 - f. Other tissue(s)/organ(s)
 - g. Frozen section tissue fragment(s)
8. Special studies (specify) (eg, histochemistry, immunohistochemistry, morphometry, DNA analysis [specify type], cytogenetic analysis) (Note **C**)

C. Microscopic Evaluation

1. Tumor
 - a. Histologic type (Note **D**)
 - b. Histologic grade (Note **E**)
 - c. Depth of invasion (Note **F**)
 - d. Venous/lymphatic vessel invasion
2. Margins (Note **H**)
 - a. Proximal
 - b. Distal
 - c. Mesenteric (radial), as indicated
3. Additional pathologic findings, if present
 - a. Adenoma(s)
 - b. Other types of polyps
 - c. Dysplasia
 - d. Crohn disease
 - e. Celiac disease
 - f. Other
4. Regional lymph nodes
 - a. Number
 - b. Number with metastases
5. Metastasis to other organ(s) or structure(s) (specify sites)
6. Other tissue(s)/organ(s)
7. Results/status of special studies (specify) (Note **C**)
8. Comments
 - a. Correlation with intraoperative consultation, as appropriate
 - b. Correlation with other specimens, as appropriate
 - c. Correlation with clinical information, as appropriate

V. Whipple Resection

(Pancreaticoduodenectomy, Partial or Complete, With or Without Partial Gastrectomy)

A. Clinical Information

1. Patient identification
 - a. Name
 - b. Identification number
 - c. Age (birth date)
 - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
 - a. Relevant history (Note **A**)
 - b. Relevant findings (eg, endoscopic/imaging studies)
 - c. Clinical diagnosis
 - d. Operative findings

B. Macroscopic Examination

1. Specimen
 - a. Organ(s)/tissue(s) included (specify)
 - b. Unfixed/fixed (specify fixative)
 - c. Dimensions (measure attached tissues individually)
 - d. Orientation
 - e. Results of intraoperative consultation
2. Tumor
 - a. Location
 - b. Configuration (Note **G**)
 - c. Size
 - d. Descriptive features (eg, color, consistency, necrosis, hemorrhage)
 - e. Estimated extent of invasion
3. Margins
4. Regional lymph nodes (Note **B**)
5. Additional pathologic findings, if present
6. Tissues submitted for microscopic evaluation
 - a. Carcinoma, including
 - (1) points of deepest penetration of surrounding structures
 - (2) points of closest approach to margins
 - (3) interface of tumor with adjacent tissues
 - b. Ampulla of Vater
 - c. Margins (Note **H**)
 - (1) proximal (gastric or duodenal)
 - (2) distal (duodenal)
 - (3) posterior pancreatic surface (deep radial margin)
 - (4) distal (duodenal) distal pancreas
 - (5) common bile duct
 - d. All lymph nodes
 - (1) regional
 - (2) non-regional
 - e. Duodenum uninvolved by tumor
 - f. Other tissue(s)/organ(s)
 - g. Frozen section tissue fragment(s) (unless saved for special studies)
7. Special studies (specify) (eg, histochemistry, immunohistochemistry, electron microscopy) (Note **C**)

C. Microscopic Evaluation

1. Tumor
 - a. Histologic type (Note **D**)
 - b. Histologic grade (Note **E**)
 - c. Extent of invasion (Note **F**)
 - d. Venous/lymphatic vessel invasion
 - e. Perineural invasion
2. Margins (Note **H**)
 - a. Proximal (gastric or duodenal)
 - b. Distal (duodenal)
 - c. Posterior pancreatic surface (deep radial margin)
 - d. Distal (duodenal) distal pancreas
 - e. Common bile duct
3. Regional lymph nodes
 - a. Number
 - b. Number with metastases
4. Distant metastasis (specify site)
5. Additional pathologic findings, if present
 - a. Adenoma(s)
 - b. Other types of polyps
 - c. Dysplasia
 - d. Crohn disease
 - e. Celiac disease
 - f. Gastritis
 - g. Other
6. Other tissue(s)/organ(s)
7. Results/status of special studies (specify) (Note **C**)
8. Comments
 - a. Correlation with intraoperative consultation, as appropriate
 - b. Correlation with other specimens, as appropriate
 - c. Correlation with clinical information, as appropriate

Explanatory Notes**A. Relevant History**

Conditions that predispose to small bowel malignancy include Crohn disease, celiac disease, inherited polyposis syndromes (including familial adenomatous polyposis, hereditary non-polyposis colon cancer and Peutz-Jeghers syndromes). Prior surgery for benign or malignant tumors, weight change, or change in body habitus are also relevant.

B. Intraoperative Consultation

Evaluation of specimens during the performance of a procedure, such as immediate evaluation of a cytologic aspirate or the intraoperative gross or microscopic examination, should be documented. The sampling of the tissue should be documented in the macroscopic evaluation, and the findings of such examination should be documented in the final report, including correlation with the final pathologic diagnosis or impression. Discrepancies, if any, should be explained in the report.

C. Special Procedures

Special procedures may include: immunohistochemical stains, histochemical stains, electron microscopy, flow cytometry, cytogenetic studies, etc. If such studies are performed in different laboratories, either interinstitutional or intrainstitutional, the responsible laboratory should be stated.

D. Histologic Type

For tumors of the small intestine, the protocol recommends the histologic classification published by the World Health Organization (WHO).¹

WHO Classification of Small Intestinal Carcinoma

Adenocarcinoma

Mucinous adenocarcinoma (greater than 50% mucinous)

Signet-ring cell carcinoma (greater than 50% signet-ring cells)[#]

Small cell carcinoma^{##}

Squamous cell carcinoma

Adenosquamous carcinoma

Medullary carcinoma

Undifferentiated carcinoma^{##}

Mixed carcinoid-adenocarcinoma

Other (specify)

[#] By convention, signet-ring cell carcinoma is always assigned grade 3 (see Note **E**).

^{##} By convention, small cell carcinoma and undifferentiated carcinoma are assigned grade 4 (see Note **E**).

The term carcinoma, NOS (not otherwise specified) is not part of the WHO classification. This protocol does not apply to carcinoid tumors, lymphoma, or stromal tumors (sarcomas) of the small intestine.

E. Histologic Grade

A histologic grading system for adenocarcinomas based on the extent of glandular formation in the tumor is recommended as shown below.

Grade X	Grade cannot be assessed
Grade 1	Well differentiated (more than 95% of tumor composed of glands)
Grade 2	Moderately differentiated (50% to 95% of tumor composed of glands)
Grade 3	Poorly differentiated (less than 50% of tumor composed of glands)

The specific definitions of the histologic grades listed above are as follows.

Grade 1	Well differentiated adenocarcinomas are composed entirely of glands or have less than 5% of solid or cord-like growth patterns.
Grade 2	Carcinomas that are moderately differentiated have from 5% to 50% solid or cord-like growth patterns.
Grade 3	Poorly differentiated carcinomas have more than 50% of solid or cord-like growth patterns.

Grade 4 is reserved for small cell carcinoma and undifferentiated carcinoma (WHO classification).

F. TNM and Stage Groupings

Surgical resection is the most effective therapy for small intestinal carcinoma, and the best estimation of prognosis is related to the anatomic extent (stage) of disease at the time of resection.

The protocol recommends the TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC), but does not preclude the use of other staging systems.²⁻⁴

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

Primary Tumor (T)

TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ
T1	Tumor invades lamina propria or submucosa
T2	Tumor invades the muscularis propria
T3	Tumor invades through the muscularis propria into the subserosa or into the nonperitonealized perimuscular tissue (mesentery or retroperitoneum [#]) with extension 2 cm or less
T4	Tumor perforates the visceral peritoneum or directly invades other organs or structures (includes other loops of small intestine, mesentery, or retroperitoneum more than 2 cm, and the abdominal wall by way of the serosa; for the duodenum only, includes invasion of the pancreas)

[#] The non-peritonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum, in areas where serosa is lacking, part of the retroperitoneum.

Regional Lymph Nodes (N)

NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis [#]
N1	Regional lymph node metastasis

[#] Regional Lymph Nodes (pN0): Isolated Tumor Cells

Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. Lymph nodes or distant sites with ITCs found by either histologic examination, immunohistochemistry, or nonmorphologic techniques (eg, flow cytometry,

DNA analysis, polymerase chain reaction [PCR] amplification of a specific tumor marker) should be classified as N0 or M0, respectively. Specific denotation of the assigned N category is suggested as follows for cases in which ITCs are the only evidence of possible metastatic disease.^{5,6}

pN0	No regional lymph node metastasis histologically, no examination for isolated tumor cells (ITCs)
pN0(i-)	No regional lymph node metastasis histologically, negative morphologic (any morphologic technique, including hematoxylin-eosin and immunohistochemistry) findings for ITCs
pN0(i+)	No regional lymph node metastasis histologically, positive morphologic (any morphologic technique, including hematoxylin-eosin and immunohistochemistry) findings for ITCs
pN0(mol-)	No regional lymph node metastasis histologically, negative nonmorphologic (molecular) findings for ITCs
pN0(mol+)	No regional lymph node metastasis histologically, positive nonmorphologic (molecular) findings for ITCs

Distant Metastasis (M)

MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

Stage Groupings

Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
	T2	N0	M0
Stage II	T3	N0	M0
	T4	N0	M0
Stage III	Any T	N1	M0
Stage IV	Any T	Any N	M1

TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

Additional DescriptorsResidual Tumor (R)

Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification,⁷ shown below.

RX	Presence of residual tumor cannot be assessed
R0	No residual tumor
R1	Microscopic residual tumor
R2	Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

Vessel Invasion

By AJCC/UICC convention, vessel invasion (lymphatic or venous) does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category. In all other cases, lymphatic and venous invasion by tumor are coded separately as follows.

Lymphatic Vessel Invasion (L)

LX	Lymphatic vessel invasion cannot be assessed
L0	No lymphatic vessel invasion
L1	Lymphatic vessel invasion

Venous Invasion (V)

VX	Venous invasion cannot be assessed
V0	No venous invasion
V1	Microscopic venous invasion
V2	Macroscopic venous invasion

G. Configuration

Configuration types include polypoid (exophytic), endophytic (ulcerating), or diffusely infiltrative (linitis plastica). Polypoid (exophytic type) may be pedunculated or sessile.

H. Margins

For segmental small bowel resections, margins include the proximal, distal, and mesenteric margins of resection. For all small bowel segments, except the duodenum, the mesenteric resection margin is the only pertinent radial margin. For pancreaticoduodenectomy specimens of carcinomas of the duodenum, the non-peritonealized surface constitutes a deep radial (non-peritonealized soft tissue) margin. In pancreaticoduodenectomy specimens performed for duodenal carcinomas, the proximal margin of stomach or duodenum (pylorus-sparing Whipple resection) and the distal resection margin of duodenum are more biologically relevant than in pancreaticoduodenectomy specimens performed for pancreatic carcinoma and should always be sampled.

References

1. Wright NH, Howe JR, Rossini FP, Shepherd NA. Carcinoma of the small intestine. In: Hamilton SR, Aaltonen LA, eds. *World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Digestive System*. Lyon: IARC Press; 2000:70-82.
2. Greene FL, Page DL, Fleming ID, et al, eds. *AJCC Cancer Staging Manual*. 6th ed. New York: Springer; 2002.
3. Sobin LH, Wittekind C, eds. *UICC TNM Classification of Malignant Tumours*. 6th ed. New York: Wiley-Liss; 2002.
4. Fielding LP, Arsenault PA, Chapuis PH, et al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Terminology (ICAT). *J Gastroenterol Hepatol*. 1991;6:325-344.
5. Wittekind C, Greene FL, Henson DE, Hutter RVP, Sobin LH, eds. *TNM Supplement. A Commentary on Uniform Use*. 3rd ed. New York: Wiley-Liss; 2003.
6. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. *Cancer*. 2003;90(12):2740-2741.
7. Wittekind C, Compton CC, Greene FL, Sobin LH. Residual tumor classification revisited. *Cancer*. 2002;94:2511-2516.

Bibliography

- Botsford TW, Crowe P, Crocker DW. Tumors of the small intestine. *Am J Surg*. 1962;103:358-365.
- Galandiuk S, Hermann RE, Jagelman DG, Fazio VW, Sivak MV. Villous tumors of the duodenum. *Ann Surg*. 1988;207(3):234-239.
- Holmes GK, Dunn GI, Cockel R, Brookes VS. Adenocarcinoma of the upper small bowel complicating coeliac disease. *Gut*. 1980; 21:1010-1016.
- Perzin KH, Bridge MF. Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma. *Cancer*. 1981;48:799-819.
- Perzin KH, Bridge MF. Adenomatous and carcinomatous changes in hamartomatous polyps of the small intestine (Peutz-Jeghers syndrome). *Cancer*. 1982;49:971-983.
- Spira IA, Ghazi A, Wolff WI. Primary adenocarcinoma of the duodenum. *Cancer*. 1977;39:1721-1726.